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The hepatocyte growth factor (HGF) also known as scatter factor activates cancer cell invasion and metastasis. We show that
in ovarian cancer cells HGF induced the phosphorylation of the small heat shock protein of 27 kDa (HSP27) by activating the
p38MAPK. HSP27 is increased in many cancers at advanced stage including ovarian cancer and associated with cancer resist-
ance to therapy and poor patients’ survival. The phosphorylation of HSP27 regulates both its chaperone activity and its con-
trol of cytoskeletal stability. We show that HSP27 was necessary for the remodeling of actin filaments induced by HGF and
that motility in vitro depended on the p38MAPK-MK2 axis. In vivo, HSP27 silencing impaired the ability of the highly meta-
static, HGF-secreting ovarian cancer cells to give rise to spontaneous metastases. This was due to defective motility across
the vessel wall and reduced growth. Indeed, HSP27 silencing impaired the ability of circulating ovarian cancer cells to home
to the lungs and to form experimental hematogenous metastases and the capability of cancer cells to grow as subcutaneous
xenografts. Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic
paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug. Altogether, these data show that
the HSP27 is required for the proinvasive and prometastatic activity of HGF and suggest that HSP27 might be not only a
marker of progression of ovarian cancer, but also a suitable target for therapy.
Genetic, experimental and clinicopathological data show that
the hepatocyte growth factor (HGF) and its tyrosine kinase
receptor MET play a fundamental role in human cancer, by
promoting growth, cell survival, angiogenesis and metasta-
sis.1–3 In particular, HGF is also known as scatter factor as it
causes tumor cells to lose contacts with neighbors and
become highly motile, initiating tumor invasion of adjacent
tissue and, ultimately, the growth of distant tumors. The
HGF/MET couple elicits these biological activities by initiat-
ing several downstream signaling pathways, such as those
involving the mitogen-activated protein kinases (MAPK), the
phosphatidylinositol 3-kinase/AKT and the AKT substrate
mammalian target of rapamycin (mTOR).4
The HGF receptor, encoded by the MET oncogene is
expressed in most epithelial cancers. In ovarian cancer, it is
expressed in 70% and overexpressed in 30% of cases.5,6 It
has been shown that HGF promotes the spread and metasta-
sis of ovarian cancer cells in preclinical models in vitro and
in vivo.7–9 High level of HGF was measured in fluids of both
benign and malignant ovarian cysts, as well as in ovarian
cancer ascites.10 Increased levels of HGF were found in sera
of patients with advanced ovarian cancers and associated to
poor prognosis.11
The small heat shock protein of 27 kDa (HSP27) encoded
by the HSPB1 gene, belongs to the family of small heat shock
proteins (HSPs), which are involved in a wide range of cellu-
lar processes and are specially known for their ability to help
cells to survive under stress conditions, for example, after
heat shock. HSP27 is a molecular chaperone with antiaggre-
gation property, as it participates in sequestering damaged
proteins12 and is involved in the proteasomal degradation of
certain proteins under stress conditions.13 Besides its role in
stressed cells, HSP27 plays crucial roles within the cell under
unstressed conditions as it provides cytoskeletal structural
stability14,15 and exerts an antiapoptotic function by binding
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crucial apoptotic proteins.16,17 The role of HSP27 in the stabili-
zation of the cytoskeleton might help promoting cell motility
and invasiveness and thereby metastasis. Together with the fre-
quent report of increased expression of HSP27 in human can-
cers at advanced stage,18 these concepts suggested that HSP27
might be a marker of cancer progression and bad prognosis,
and that targeting HSP27 could be a therapeutic strategy.
HSP27 is regulated at transcriptional and post-
transcriptional levels. The synthesis of HSP27 can be induced
not only by heat shock and other stress conditions, but also by
physiological stimuli such as those regulating differentiation.19
HSP27 can oligomerize12 and oligomerization is regulated by
phosphorylation.20,21 Specific changes in oligomerization and
phosphorylation allow HSP27 to interact with definite polypep-
tides and to modulate their folding, activity and half-life. This
links HSP27 to multiple and specific cellular functions.20 For
example the small phosphorylated HSP27 oligomers appear to
be the active form having F-actin capping activity and nega-
tively modulating the growth of F-actin fibers,15 while larger
but unphosphorylated oligomers of different size bind and sta-
bilize polypeptides such as STAT-3, procaspase-3 and histone
deacetylase 6 preventing their degradation.22
HSP27 phosphorylation is catalyzed by a large number of
kinases, among which the MAPKAPK2 mitogen-activated
protein kinase-activated protein kinase 2 (MK2).21 MK2 is a
substrate of the 38 kDa mitogen-activated protein kinase
(p38MAPK) that is activated by the HGF and is necessary
for HGF triggered motility.23 Altogether these data prompted
us to investigate the role played by HSP27 in the HGF trig-
gered metastasis.
Material and Methods
Cell lines and reagents
TOV-21G and SK-OV-3 cell lines were from the American
Type Culture Collection (Manassas, VA), acquired from LGC
Standards (Teddington, London, UK). OVCAR-3 cells were
from the NCI-60 collection, acquired from Charles River (Wil-
mington, MA). All cell lines were purchased in 2011 and
grown as indicated by the provider. HGF was purchased from
RayBiotech (Norcross, GA). Paclitaxel (PTX) was obtained
from Teva Pharmaceutical Industries (Petah Tikva, Israel).
Lentiviral infection
Stable silencing of HSP27 was achieved using the shRNAs
transduced with lentiviral vectors. MISSIONV
R
shRNAs for
HSP27 and the control one were purchased from Sigma-
Aldrich (Saint Louis, MO). SK-OV-3 cells were engineered to
produce and secrete HGF as previously described.24 pGIPZ
shRNAs for HSP27 and the control one were purchased from
Thermo Fisher Scientific (Waltham, MA) and used to silence
HSP27 for the study of spontaneous metastases in vivo (see
below). SK-OV-3 cells were transduced with the dominant
negative p38MAPK mutant as previously described.25 To
study hematogenous metastases, the stable expression of
luciferase and GFP was obtained using the pRRL.sin.PPT.
CMV.Luciferase.iresEMCVwt.eGFP.pre lentiviral vector
kindly provided by Dr. Elisa Vigna. The LV vectors were
produced and used as reported previously.25
Western blotting and antibodies
Western blotting was carried out as described previously.25
The HSP27, antitubulin phospho-HSP27 (Ser15, 78 and 82),
phospho-p38MAPK, phospho-MK2 and phospho-c-Met anti-
bodies were from Cell Signaling Technology (Beverly, MA);
the c-Met antibody was from Invitrogen (Paisley, Scotland,
UK); the actin antibody was from Santa Cruz Biotechnology
(Santa Cruz, CA); the vinculin antibody was from Sigma-
Aldrich. Primary antibodies were detected using the appro-
priate peroxidase-conjugated secondary antibody (Jackson
Immunoresearch, Newmarket, Suffolk, UK), and revealed by
PierceV
R
ECL Western Blotting Substrate (Rockford, IL).
Quantitative RT-PCR
Quantitative RT-PCR was performed as described.26 Primer
sets and PCR cycling conditions are available from the
authors.
Immunofluorescence
SK-OV-3 cells grown on glass coverslips, left untreated or
treated for 6 hr with HGF or PTX, were fixed with parafor-
maldehyde and permeabilized. After blockade, cells were
incubated for 1 hr at room temperature with the primary
antibody, for 30 with the secondary antibodies (donkey anti-
mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 555, Invi-
trogen) and then stained with DAPI. For F-actin staining, the
Alexa Fluor 555-phalloidin was used (Invitrogen). Coverslips
were then mounted using the fluorescence mounting medium
(Dako, Glostrup, DK) and analyzed using a confocal laser
scanning microscope (TCS SPE II; Leica, Wetzlar, D)
equipped with 633/1.40 oil-immersion objective. For F-actin
What’s new?
Hepatocyte growth factor, HGF, induces cancers to spread. Recently, researchers learned that it activates a small heat shock
protein, HSP27, which is increased in advanced stage cancers, and associated with resistance to chemotherapy. In this paper,
the authors showed that silencing HSP27 stopped ovarian cancer cells from metastasizing. Suppressing HSP27 also sensitized
the tumors to Paclitaxel. The results show that HSP27 is important for metastasis and invasion, and could make a promising
target for therapy.
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quantification, three independent experiments were per-
formed and four fields per coverslip were scanned for each
experiment. To quantify the fluorescent signal associated to
555-phalloidin the ImageJ software was used (Wayne Ras-
band, National Institute of Health, Bethesda, MD). The fluo-
rescence values were then normalized to the number of
nuclei for each field.
Motility and migration assays
For the scatter assay, SK-OV-3 cells were seeded in triplicate
at 1,500 cells/well in 24-well plates in complete medium.
Once cells formed compact colonies, they were treated with
50 ng/ml HGF for 24 hr. For the motility assay, 6 3 104 SK-
OV-3 were seeded in duplicate in the upper compartment of
the Transwell chamber (BD FalconTM, Franklin Lakes, NJ)
and medium containing 50 ng/ml HGF was added in the
lower compartment for 5 hr. In both assays, after stimulation
cells were fixed with 11% glutaraldehyde and stained with
0.1% crystal violet in 20% methanol solution (Sigma Aldrich);
photographs were taken by optical microscope. For both
assays, three independent experiments were performed. For
the motility assay four fields/insert/experiment were photo-
graphed and analyzed with ImageJ software.
In vivo experiments
For the measure of spontaneous metastasis, SK-OV-3 cells
were engineered to secrete HGF and, when indicated, to
express either a control or a HSP27 specific shRNA using
lentiviral vectors carrying the GFP transgene under a differ-
ent promoter. Cells expressing GFP uniformly were sorted
using MoFloTM XDP (Beckman Coulter, High Wycombe,
UK). A total of 5 3 105 sorted cells were injected subcutane-
ously (s.c.) in the right posterior flank of 6-week-old NOD/
SCID mice (Charles River Laboratories). Animals (seven mice
per group) were sacrificed and the lungs examined when
tumors reached the volume of 300–500 mm3 (i.e., 6 weeks
after the injection). The lungs were removed and fixed. Fluo-
rescent acquisition images were collected with IVISV
R
Lumina
II (Caliper Life Sciences, Hopkinton, MA), using excitation
wavelength of 465 nm and detection of 520 nm for GFP, a
field of view of 5 cm, a time exposure of 0.5 min, with
medium sensitivity binning. Images were processed using Life
Science’s Living Image software and the total number of lung
surface metastasis foci was counted.
For the measure of hematogenous metastases, control and
HSP27-silenced SK-OV-3 were transduced with lentiviral vec-
tors containing the luciferase and GFP expression vector.
Cells were sorted according to the GFP expression using
MoFloTM XDP (Beckman Coulter, High Wycombe, UK).
Subsequently, 3 3 105 sorted control and HSP27-silenced
SK-OV-3 were injected in the tail vein of female CD1 nude
mice (six mice per group, Charles River Laboratories). To
monitor the formation lung colonies through time, biolumi-
nescent acquisitions images were collected by means of the
IVISV
R
Lumina II imaging system, after intraperitoneal injec-
tion of luciferine (150 mg/kg body weight). Detection of bio-
luminescent signal was acquired using a field of view of 12.5
cm, a time exposure of 1 min, with high sensitivity binning.
After 2 months from cells injection, mice were sacrificed
immediately after luciferine injection and lung explants were
visualized by IVISV
R
Lumina II. Images were processed using
Life Science’s Living Image software and the total number of
metastatic foci at lung surface was determined.
Short-term lung colonization assay was carried to evaluate
cell homing to the lungs by labeling 5 3 105 SK-OV-3 con-
trol cells with cellTrace
TM
CFSE (Molecular probes, USA) and
5 3 105 HSP27 silenced SK-OV-3 cells with cellTrace
TM
VIO-
LET (Molecular probes). Cells were mixed in 200 ml PBS and
three mice (NOD/SCID) for each time point were injected
intravenously. Lungs were explanted 2 and 24 hr after injec-
tion and fixed. Microscopy imaging was performed using a
Leica TCS SP5-AOBS 5-channel confocal and multiphoton
system (Leica Microsystems) equipped with a pulsed femto-
second Ti:Sapphire (Ti-Sa) Chameleon Vision II laser
(Coherent), tunable for excitation from 680 to 1,080 nm.
Violet, CFSE were captured by two detection channels. The
two-photon laser was tuned to a wavelength of 700 and 985
nm for the first and second channel respectively. Emission
wavelengths of 400–476 nm (blue, violet) and 490–539 nm
(green, CFSE) were collected. Images of the tissues were
taken using a HCX PL APO CS 203/0.7 NA oil immersion
objective. Series of x-y-z images (typically 0.75 3 0.75 3 2.5
mm3 voxel size) were collected along the z-axis at 2.5 mm
intervals throughout the tissues (30–50 mm) depth, images
were then analyzed with ImageJ software.
To study the sensitization of HSP27-silenced tumors to
PTX, 3 3 106 control and HSP27-silenced SK-OV-3 were
injected s.c. in the right posterior flank of 6-week-old female
CD1 nude mice (Charles River Laboratories). When tumors
were palpable, mice were divided in experimental groups of
six animals and treated with 20 mg/kg PTX by i.v. injection
once a week for 4 weeks. Control animals were treated with
vehicle. Tumor dimensions were evaluated using a caliper
and were calculated using the formula (D 3 d2)/2, where D
is the major tumor axis and d is the minor tumor axis. All
animal procedures were approved by the Veterinary Ethical
Commission of the I.R.C.C. and by the Italian Ministry of
Health.
Results
HGF triggers HSP27 phosphorylation in ovarian
cancer cell lines
We studied three ovarian cancer cell lines, representative of
the genetic heterogeneity of human ovarian cancer: SK-OV-3,
TOV-21G and OVCAR-3. Their genetic profiles are reported
at http://www.sanger.ac.uk/perl/genetics/CGP/core_line_vie-
wer?action5cell_lines and Ref. 27. For example, SK-OV-3
cells show deletions of the CDKN2a and TP53 genes and a
PIK3CA mutation; TOV-21G cells have wild-type TP53 and
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FANCF inactivated by methylation and OVCAR-3 cells carry
a TP53 mutation and show PIK3CA amplification.
In all three ovarian cancer cell lines, both the MET recep-
tor for HGF and HSP27 are consistently expressed (Fig. 1a).
HGF stimulation induced the phosphorylation of HSP27.
Basally, HSP27 phosphorylation was barely detectable, while
after stimulation with HGF phosphorylation was observed at
the three main phospho-acceptor serine residues (Fig. 1a),
which are Ser15, Ser78 and Ser82 in humans.21 HSP27 phos-
phorylation was associated to the phosphorylation of the
p38MAPK and MK2, which are the best characterized
kinases leading to HSP27 phosphorylation. We confirmed the
involvement of the p38MAPK-MK2 cascade by transducing
cells with the dominant negative p38MAPK mutant.25 In the
absence of a functional p38MAPK, neither MK2 nor HSP27
were phosphorylated upon HGF stimulation (Fig. 1b), indi-
cating that the HGF-triggered phosphorylation of HSP27 at
the Ser15, Ser78 and Ser82 depended on the activation of
p38MAPK.
HGF-triggered ovarian cancer cell motility is impaired by
HSP27 silencing and by inhibition of the p38MAPK/MK2
axis
HGF, also known as scatter factor, is able to induce
epithelial-to-mesenchymal transition and cell motility.1,4 As
HSP27 controls actin filament polymerization,15 we evaluated
if HSP27 is involved in the motility induced by HGF in ovar-
ian cancer cells. HSP27 was stably silenced with specific
short-hairpin RNAs carried by lentiviral vectors (Fig. 2a) in
the SK-OV-3 ovarian cancer cells and cell motility was
evaluated in the scatter and in the migration assays (Figs. 2b
and 2e).
Sparse SK-OV-3 cells grew on plastic forming packed
islands with cell-to-cell contacts mimicking the structure of
an epithelial sheet. Addition of HGF to cell culture medium
causes loss of cell junctions and cell dispersal throughout the
culture dish (scatter). Figure 2b shows that HSP27 silencing
impaired the capability of SK-OV-3 cells to scatter upon
HGF stimulation.
As it is known that HSP27 affects the polymerization of
actin filaments, confocal analysis and phalloidin staining were
used to measure the amount of F-actin in HSP27-silenced
and control cells left untreated or treated with HGF (Fig. 2c).
As shown by the phalloidin staining and the relevant quanti-
fication (Figs. 2c and 2d, respectively), HSP27 silencing
resulted in the decrease of F-actin.
The migratory capability of HSP27-silenced and control
cells was measured with the modified Boyden chamber assay
that uses the TranswellV
R
permeable support. Figure 2e shows
that HSP27 silencing impaired the ability of HGF to induce
cell migration through permeable filters. Moreover, to con-
firm the role of the p38MAPK/MK2 axis in linking MET
activation by HGF to HSP27 function, we inhibited either
p38MAPK or MK2, by expressing a dominant negative
p38MAPK form (see above) or by treating cells with the
MK2 biochemical inhibitor III, which inhibits not only MK2
but also the MK5 and MK3 substrates of p38MAPK. As
shown in Figure 2f, the inhibition of either components of
the axis resulted in abrogation of HGF stimulated cell migra-
tion. Altogether these data suggested that the p38MAPK/
MK2/HSP27 pathway plays a key role in the control of HGF-
dependent ovarian cancer cells motility.
HSP27 silencing impairs the prometastatic activity of HGF
in ovarian cancer cells
Cell motility is a prerequisite for cancer cell to disseminate
and to home in a distant site in the multistep process of
Figure 1. HGF triggers HSP27 phosphorylation in ovarian cancer
cell lines. Expression and phosphorylation of proteins in the
SK-OV-3, TOV-21G and OVCAR-3 ovarian cancer cell lines were
evaluated with Western-blot analysis of total cell extracts. (a)
HGF-induced HSP27 phosphorylation (P-HSP27) was evaluated with
Western-blot analysis using antibodies specific for each phospho-
rylated residue (serines 15, 78 and 82). Activation of MET (P-MET),
p38MAPK (P-p38MAPK) and MK2 (P-MK2) were evaluated by label-
ing the phosphorylated forms with phospho-specific antibodies. All
ovarian cancer cell lines were stimulated with 50 ng/ml HGF at dif-
ferent time points are indicated. When possible, the same blots
were probed sequentially. All blots were re-probed for vinculin to
confirm equal loading. (b) The dependence of the phosphorylation
of HSP27 on p38MAPK was assessed by transducing SK-OV-3 cells
with the dominant negative p38MAPK mutant (DN-p38) and
stimulating cells with 50 ng/ml HGF at different time points as
indicated. Western-blot analysis and antibodies used were as in
panel (a).
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Figure 2. HSP27 silencing and inhibition of the p38MAPK-MK2 pathway impair HGF-triggered ovarian cancer cell motility. (a) HSP27 was silenced
stably in SK-OV-3 cells with two different short-hairpin RNAs (shHSP27 I and II). As a control, cells were transduced to express a scramble short-
hairpin RNA sequence (shCTRL). Expression of HSP27 was assayed in control and HSP27-silenced cells with Western-blot analysis. The blot was
re-probed for actin to confirm equal loading. (b) Scatter assay was performed to evaluate the HGF-induced motility of SK-OV-3 cells. Colonies
formed by control and HSP27-silenced were left untreated or treated with 50 ng/ml HGF for 24 hr. Photographs were taken with an optical
microscope. The results of a representative experiment are shown. HGF triggered the dispersal of cells (scattering) was impaired in HSP27
silenced cells. (c) HGF-triggered actin polymerization was evaluated by confocal microscopy. Control and HSP27-silenced SK-OV-3 cells were left
untreated or treated with 50 ng/ml HGF for 6 hr. The antibody for human HSP27 was used together with phalloidin that binds F-actin. Nuclei
were stained with DAPI. Scale bar: 15 lm. (d) Phalloidin fluorescence signal was quantified by ImageJ software to evaluate the amount of
F-actin. Data are the mean 6 SEM. The p value was calculated vs. control cells (***p < 0.001) by ANOVA test. (e) TranswellV
R
permeable supports
were used to evaluate the migratory capability of SK-OV-3 toward a chemotactic stimulus such as HGF. Control and HSP27-silenced SK-OV-3
cells were plated in the upper chamber and left untreated or treated with 50 ng/ml HGF for 5 hr. Photographs of the lower side of the filters
(insets in the graph) were taken with an optical microscope and ImageJ software was used to quantify the area covered by cells. Five independ-
ent experiments were performed and data are the mean 6 SEM. The p value was calculated vs. control cells (***p < 0.001) by ANOVA test. (f)
Transwell
VR
permeable supports were used as in panel (e) to evaluate the effect of inhibiting either p38MAPK or MK2 onto the migratory
capability of SK-OV-3 toward HGF. Control SK-OV-3 cells or SK-OV-3 cells expressing DN-p38MAPK were plated in the upper chamber and left
untreated or treated with 50 ng/ml HGF for 5 hr. The suppression of HSP27 phosphorylation by DN-p38MAPK is shown in Figure 1b. Alternatively,
SK-OV-3 cells in the upper chamber were treated with the MK2 inhibitor III (20 lM) for 16 hr and, when indicated, with HGF. Photographs of the
lower side of the filters (insets in the graph) were taken with an optical microscope and ImageJ software was used to quantify the area covered
by cells. Three independent experiments were performed and data are the mean 6 SEM. The p value was calculated vs. control cells
(**p < 0.01) by ANOVA test. The inhibition of HSP27 phosphorylation by the MK2 inhibitor III is shown in the inset.
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metastasis. Thus, we evaluated whether HSP27 was involved
in the prometastatic activity of HGF in ovarian cancer cells
in vivo.
SK-OV-3 cells were engineered to produce and secrete
HGF as described.24 HSP27 silencing was obtained (Figs. 3a
and 3b) using a specific shRNA driven by a lentiviral vector
carrying also the GFP transgene to allow cell sorting and to
facilitate the detection of metastases. Cells were injected subcu-
taneously in immune-compromised mice. HGF-secreting cells
formed tumors that showed a high propensity to give sponta-
neous metastases (Figs. 3c and 3d). After HSP27 silencing, the
HGF-secreting tumors showed a slightly delayed growth (data
not shown) and formed a smaller number of spontaneous
metastases (Figs. 3c and 3d). Notably, no correlation was
detectable between the volume of each primary tumor and the
number of metastases formed (data not shown).
These data suggest that HSP27 plays an important role in
the HGF-triggered metastatic process and possibly in the pro-
cess of metastasis in general. HSP27 silencing might have
impaired some of the biological properties required for the
accomplishment of the process, such as local invasion, intrav-
asation, survival in the bloodstream, extravasation and
growth at distant sites.
HSP27 silencing impairs the ability of ovarian cancer
cells to form experimental metastases
To evaluate the role of HSP27 in the cell capability to survive
in the bloodstream, to migrate across the vessel wall and to
Figure 3. HSP27 silencing impairs the ability of ovarian cancer cells to give rise to spontaneous metastases. SK-OV-3 cells were engineered
to secrete HGF and to express either HSP27 specific (shHSP27) or control shRNA (shCTRL) driven by lentiviral vectors carrying also the GFP
transgene. Cells were injected subcutaneously in immune-compromised mice and spontaneous metastases formed by SK-OV-3 xenografts
were evaluated, by examining lungs when primary tumors have reached similar volumes. (a) Silencing of HSP27 in the HGF-secreting, GFP
expressing cells, measured with quantitative RT-PCR. (b) Silencing of HSP27 in the HGF secreting injected cells and in tumors grown subcu-
taneously, evaluated using Western-blot analysis of HSP27. (c) Quantification of lung metastatic foci visualized as fluorescent dots by
means of the IVIS
VR
Lumina II imaging system. The average number of metastases in seven mice in a representative experiment is shown.
Student’s t-test *p < 0.05; all average values of data were expressed as mean 6 SEM. (d) Representative ex vivo fluorescent images of the
lungs (left and right lobes are separated) of mice with metastatic foci. Fluorescent intensity is expressed as radiance efficiency (p/s/cm2/
sr/mW21/cm2).
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Figure 4. HSP27 silencing diminishes cell ability to form experimental hematogenous metastases and impairs cell homing to the lungs. (a)
Silencing of HSP27 in the injected SK-OV-3 cells expressing luciferase and GFP, measured with quantitative RT-PCR. (b) Silencing of HSP27
in the injected cells, evaluated using Western-blot analysis of HSP27. (c) Quantification of lung metastatic foci visualized as bioluminescent
dots by means of the IVIS
VR
Lumina II imaging system. The average number of metastases in five mice in a representative experiment is
shown. Student’s t-test **p < 0.01; all average values of data were expressed as mean 6 SEM. (d) Representative ex vivo bioluminescent
images of lungs of two mice, visualized 2 months after the inoculum of luciferase-positive SK-OV-3 cells into the tail vein; bioluminescence
intensity is expressed as radiance (p/s/cm2/sr). (e) Detection in the lung of control and HSP27 silenced SK-OV-3 cells (silencing is shown
in Fig. 2) labeled with cellTrace
TM
CFSE (green) and VIOLET (violet), respectively; cells were mixed and injected intravenously; after 2 and 24
hr (h) lungs were explanted and fixed; cells were visualized with confocal microscopy and representative fields are shown. (f) Ratio between
green and violet fluorescent cells in the lungs. Lungs of three mice for each time point were examined and at least four fields per lung
were acquired. For each field a Z-stack acquisition of several slices was made. For image analysis with ImageJ software, a maximum inten-
sity projection was made for all fields before quantifying the area covered by cells for each single channel. Data are the mean 6 SEM The
p value was calculated using the Student’s t-test (*p < 0.05).
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form lung colonies, cell ability to form experimental hema-
togenous metastases was measured. HSP27-silenced and con-
trol SK-OV-3 cells (Figs. 4a and 4b) were stably transduced
with lentiviral vectors carrying a luciferase-IRES-GFP trans-
gene, so that GFP-expressing cells were isolated by cell sort-
ing. Sorted cells were injected into the tail vein of immune-
compromised mice and the formation of lung colonies was
evaluated after 21 days. Luciferine injection allowed the mon-
itoring of animals in time and the measure of lung coloniza-
tion. Figures 4c and 4d show that control SK-OV-3 cells
formed experimental metastases, which were almost abro-
gated by HSP27 silencing.
To assess the role played by the homing of cells to the
lung versus cell ability to proliferate in the formation of
experimental metastases, short-term colonization was eval-
uated by injecting in the tail vein simultaneously the HSP27
silenced and control cells differentially labeled with two com-
pounds that, once inside the cells, are cleaved to generate
two different fluorescent dyes, violet and green, respectively.
Two hours after injection, confocal microscopy allowed the
detection of the same number of cells in the lungs, while
after 24 hr green cells, i.e., control cells, were more numerous
than the violet-labeled HSP27 silenced cells (Figs. 4e and 4f).
HSP27 is necessary for the growth of ovarian cancer cells
in vivo and protects cells from the chemotherapeutic PTX
The inability of HSP27 silenced cells to form lung colonies
might be due also to their inability to proliferate. In vitro,
HSP27 silencing did not affect the proliferation rate of con-
trol and HGF-secreting ovarian cancer cells (data not shown).
Conversely, in vivo HSP27 silencing reduced significantly the
subcutaneous growth of control ovarian cancer cells (Fig. 5a).
As mentioned before, also the growth in vivo of the HGF-
secreting cells was slightly delayed.
Nonetheless, even in vivo the growth of control ovarian
cancer cells was not fully abrogated by HSP27 suppression.
Thus, we wondered whether suppression of HSP27 might
sensitize cells to PTX in vivo, as it sensitizes bladder28 and
prostate29 cancer cells in vivo and an ovarian cancer cell line
in vitro.30 We found that also SK-OV-3 cells are sensitized to
PTX in vitro (not shown). We thus studied the effect of PTX
on the in vivo growth of HSP27-silenced ovarian cancer cells
as subcutaneous tumors. PTX was administered at low doses,
to which control cells were completely unresponsive (Fig.
5a). HSP27-silencing blocked the in vivo growth in response
to PTX (Fig. 5a). As HSP27 binds microtubules and likely
stabilizes them,31 we investigated whether HSP27 loss and
PTX affected microtubules of ovarian cancer cells, using
tubulin staining and confocal microscopy (Fig. 5b). HSP27
silencing alone did not affect microtubules. PTX at the used
doses did not change the architecture of microtubules. Con-
versely, in response to PTX, HSP27-silenced cells showed a
round shape indicative of cell shrinkage likely due to the
bundling of microtubules (Fig. 5b). These results underscored
the importance of HSP27 in the response of ovarian cancer
cells to PTX.
Discussion
This article shows that HGF elicits phosphorylation of
HSP27, through the p38MAPK-MK2 pathway, and that this
phosphorylation is necessary for the prometastatic capability
of HGF. This is in line with the notion that stimuli other
than heat shock can induce phosphorylation of HSP27.21
Phosphorylation induced by HGF occurred at all three best
characterized serines, which are the phospho-acceptor sites in
Figure 5. HSP27-silencing impairs ovarian cancer cell growth and
sensitizes them to PTX treatment in vivo, by affecting microtubule
architecture. (a) The involvement of HSP27 in the growth of SK-OV-
3 and in their response to PTX was evaluated in vivo. Control and
HSP27-silenced SK-OV-3 cells were injected in the flank of CD1
nude mice. When tumors were overtly palpable, mice were left
untreated or treated with 20 mg/kg i.v. PTX once a week for 4
weeks. The black arrow indicates the beginning of treatment. Data
are the mean 6 SEM. (b) Microtubule architecture upon PTX treat-
ment was studied by confocal microscopy. Control and HSP27-
silenced SK-OV-3 cells were left untreated or treated with 100 nM
PTX for 6 hr. The antibodies for human HSP27 and tubulin were
used together with DAPI for nuclear staining. Scale bars: 15 lm.
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vivo and are all involved in regulating HSP27 functions.21
Several studies have addressed the contribution of single
phosphorylation of Hsp27 at Ser-15, Ser-78 or Ser-82 in bio-
logical processes but did not allow ascribing restricted func-
tions to each residue. Depending on cell context and
stimulus, HSP27 phosphorylation is regulated by several pro-
tein kinases involved in cell survival, proliferation and motil-
ity, such as MK2, MK3, MK5, AKT, RSK, PKA, PKC and
PKD.21 Here, we show that, in ovarian cancer cells, HSP27
phosphorylation induced by HGF at all three serines was
suppressed by the expression of a dominant negative form of
the p38MAPK. This was not surprising as it was already
reported that p38MAPK plays a key role in the motility trig-
gered by HGF.23
It is known that the phosphorylation of HSP27 results in
change of conformation of the protein and thus impairment
of aggregation and release of the inhibition of actin polymer-
ization, i.e., increased actin dynamics.15 In agreement, in
ovarian cancer cells HSP27 silencing suppressed the HGF
dependent remodeling of actin filaments and the scattering
and motility triggered by HGF through permeable filters. The
role of HSP27 in the dynamics of other cytoskeletal compo-
nents such as microtubules and intermediate filaments might
be also important.14 The gain-of-function mutations of the
HSP27-encoding HSPB1 gene, which cause the axonal
Charcot-Marie-Tooth disease and distal hereditary motor
neuropathy,32 result in an increased stabilization of microtu-
bules that is incompatible with motility and mitosis.31 More-
over, HSP27 interacts also with intermediate filaments and
regulates their aggregation.33
HSP27 suppression inhibited the formation of spontane-
ous metastases triggered by HGF. Data show that HSP27 is
important in both the regulation of extravasation in vivo, as
homing and experimental hematogenous metastasis are
impaired by HSP27 silencing. Moreover, HSP27 regulates in
vivo growth of ovarian cancer cells. These data suggest that
HSP27 might be involved in the control of ovarian cancer
metastasis. A role of HSP27 in metastasis has been suggested
also by preclinical models of head and neck squamous cell
carcinoma34 and breast carcinoma.35,36 Moreover, clinical
data correlated tumor progression and expression of HSP27
in several tumor types. HSP27 is highly expressed in many
cancers, such as breast, prostate, colorectal and pancreatic
carcinomas and in many instances has been associated with
aggressive behavior, metastasis and poor prognosis.18 How-
ever, HSP27 expression correlates with good prognosis in
some tumors, like endometrial and esophageal carcino-
mas.37,38 In line with the possible Janus-like properties of
HSP27,39 a genetic variant of the promoter of the HSP27-
encoding HSPB1 gene has been associated to both an
increased lung cancer risk and a favorable survival in patients
with advanced lung cancer, as this variant results in a
reduced level of the HSP27 protein.40
In ovarian cancer too, the role played by HSP27 is contro-
versial. A higher HSP27 content was found in tumors from
patients with advanced stage cancers and was associated with
reduced survival and tumor progression after chemother-
apy.41–44 Nevertheless, a correlation between high level of
HSP27 and better prognosis of ovarian cancer patients was
also described.45 It is important to assess the role played by
HSP27 in the progression of ovarian cancer, because this is
the most lethal gynecological malignancy, which is often
diagnosed at a late stage, after tumor cells are widely meta-
stasized within the peritoneal cavity. Despite aggressive treat-
ment, which includes surgical cytoreduction followed by
combination chemotherapy with taxanes, such as PTX and
platinum drugs, such as carboplatin, more than two-thirds of
all patients succumb to the disease.46 Preclinical data shown
here suggest that in ovarian cancer HSP7 is more likely a
marker of progression and resistance to chemotherapy.
Indeed, we show also that HSP27 suppression sensitized
ovarian cancer cells to treatment with PTX in vivo, as well as
it sensitizes prostate and bladder carcinoma cells to PTX in
vivo28,47 and breast cancer cells to doxorubicin in vitro.48
Sensitization is likely due to the bundling of microtubules,
which is thought to be the correlate of the lethal effect of
PTX.49 Interestingly, PTX caused bundling of microtubules
only in HSP27-silenced ovarian cancer cells. The lack of
effectiveness of PTX in vivo and on microtubules in vitro in
HSP27-expressing cells was likely due to their partial resist-
ance to the used doses of PTX. This is important in the case
of ovarian cancer, as first-line therapy includes taxanes and
these drugs are also frequently used in the subsequent lines
of treatment. Thus, HSP27 targeting might be envisaged to
circumvent resistance to this drug commonly used in ovarian
cancer treatment.
HSP27 silencing was alone able to delay the growth of
ovarian cancer cells in vivo, while HSP27 silenced cells sur-
vived and proliferated in vitro, suggesting that the microen-
vironment causes cellular stress in vivo that requires HSP27.
This finding was unexpected, as prostate cancer cells growing
in vivo display less expression of HSP27 and other HSPs
than in vitro.50 It is also possible that the role of HSP27 in
cytoskeletal dynamics is more crucial in cells growing in vivo
than in vitro. Alternatively, it might be hypothesized that
HSP27 is necessary to circumvent physiological proapoptotic
signals in vivo as HSP27 phosphorylation and/or expression
are upregulated by several cytokines and by a number of
transcription factors other than HSF1, respectively.
As HSP27 functions as a regulatory “hub” in multiple sig-
naling and transcriptional pathways, it is an attractive thera-
peutic target. HSP27 inhibition may simultaneously suppress
many pathways implicated in cancer progression and resist-
ance to hormone and chemotherapy. Suppression of HSP27
reduces the growth in vivo of androgen resistant prostate
cancer cells29 and urinary bladder cancer cells,28 reduces pro-
gression of breast cancer cells51 and sensitizes pancreatic can-
cer cells to chemotherapy.52 In preclinical models,
suppression was obtained with small interfering RNAs and
peptide aptamers.53 The newly developed modified HSP27
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antisense has proved its effectiveness in preclinical mod-
els28,29,47,52 and is undergoing clinical trials. In the Phase I
trials, reduction in tumor markers was observed in patients
with prostate and ovarian cancer.18
In conclusion, data presented here suggest that HSP27 is
not only required for the HGF triggered invasion and metas-
tasis, but is also a necessary part of the machinery required
for the progression of ovarian cancer and for sensitization to
chemotherapeutics. Therefore, HSP27 is likely a biomarker of
advanced stage ovarian cancer and of cancer resistance to
therapy. More importantly, the preclinical data shown here
proved that the growth and dissemination of ovarian cancer
cells require HSP27 and, thus, that HSP27 might be targeted
to improve the treatment of ovarian cancer patients.
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